Licensing · MENA · Announced 8 Oct 2026
OneSource Specialty Pharma → Avalon Pharma
Licensing deal between OneSource Specialty Pharma (India) and Avalon Pharma (Saudi Arabia), covering Tirzepatide multi-dose pen, announced 8 Oct 2026. Value: Undisclosed.
Parties: OneSource Specialty Pharma (India) → Avalon Pharma (Saudi Arabia)
- Deal type
- Licensing
- Value
- Undisclosed
- Territory
- Saudi Arabia first, then selected MENA markets — launches sequenced market-by-market following relevant patent expiries
- Therapeutic area
- Metabolic / Diabetes
- Asset
- Tirzepatide multi-dose pen — generic of Mounjaro® KwikPen® (six dosages, 2.5mg–15mg)
- Announced
- 8 Oct 2026
Our analysis
Why this matters.
Avalon Pharma — the Tadawul-listed Saudi manufacturer — has signed an exclusive 10-year licensing agreement with India's OneSource Specialty Pharma to register and commercialise generic tirzepatide multi-dose pens across Saudi Arabia and selected MENA markets. The agreement was signed on 8 October; the commercial logic is signed years before the commercial opportunity: launches are sequenced market-by-market, only after relevant patent expiries . Avalon is not waiting for the patent cliff — it is pre-positioning for it, with the registration dossier already secured.
The full analysis is free to read with a work email on this page.
Source: Mubasher